Host |
Mouse |
Klon |
ZM64 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human vWF protein (aa1815-1939) |
Lokalisation |
Cytoplasm |
Factor VIII-R
|
Zeta Corporation |
ZM64 |
7 ml |
Ready-to-use |
CE/IVD |
Z2393MP |
-
|
Host |
Mouse |
Klon |
ZM64 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human vWF protein (aa1815-1939) |
Lokalisation |
Cytoplasm |
Factor VIII-R
|
Zeta Corporation |
ZM64 |
0.5 ml |
Concentrate |
CE/IVD |
Z2393MS |
-
|
Host |
Mouse |
Klon |
ZM64 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Tonsil. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant fragment of human vWF protein (aa1815-1939) |
Lokalisation |
Cytoplasm |
Factor VIII-R
|
Zeta Corporation |
ZM64 |
0.1 ml |
Concentrate |
CE/IVD |
Z2393MT |
-
|
Host |
Mouse |
Klon |
F8/86 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
F8/86 |
1 ml |
Concentrate |
CE/IVD |
MOB196 |
-
|
Host |
Mouse |
Klon |
F8/86 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
F8/86 |
0.1 ml |
Concentrate |
CE/IVD |
MOB196-01 |
-
|
Host |
Mouse |
Klon |
F8/86 |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Tonsil |
Verdünnung |
1:15 - 1:30 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
F8/86 |
0.5 ml |
Concentrate |
CE/IVD |
MOB196-05 |
-
|
Host |
Mouse |
Klon |
F8/86 |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Pepsin |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
F8/86 |
6 ml |
Ready-to-use |
CE/IVD |
PDM019 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
F, P |
Vorbehandlung |
Trypsin or Pepsin (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR014 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Pepsin (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP012 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Pepsin (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP012-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Trypsin or Pepsin (optional) |
Positivkontrolle |
Tonsil |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm |
Factor VIII Related Antigen (von Willebrand Factor)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP012-05 |
-
|
Host |
Rabbit |
Klon |
SP196 |
Format |
Concentrate |
Methode |
P |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Factor XIIIa
|
Zytomed Systems GmbH |
SP196 |
0.5 ml |
Concentrate |
RUO |
506-4962 |
-
|
Host |
Rabbit |
Klon |
SP196 |
Format |
Concentrate |
Methode |
P |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Factor XIIIa
|
Zytomed Systems GmbH |
SP196 |
1 ml |
Concentrate |
RUO |
506-4964 |
-
|
Host |
Mouse |
Klon |
E980.1 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA o Citrate |
Positivkontrolle |
Dermatofibroma, placenta or skin |
Verdünnung |
1:100 |
Isotyp |
Mouse IgG1 |
Verdünnung |
Factor XIIIa C-terminus |
Lokalisation |
Cytoplasmic |
Factor XIIIa
|
Biocare Medical |
E980.1 |
0.1 ml |
Concentrate |
CE/IVD |
CM357AK |
-
|
Host |
Mouse |
Klon |
ZM84 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Capillary hemangioma, dermatofibroma, and placenta. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant fragment of human Factor XIIIa protein |
Lokalisation |
Cytoplasm and Nucleus |
Factor XIIIa
|
Zeta Corporation |
ZM84 |
1.0 ml |
Concentrate |
CE/IVD |
Z2394ML |
-
|
Host |
Mouse |
Klon |
ZM84 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Capillary hemangioma, dermatofibroma, and placenta. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant fragment of human Factor XIIIa protein |
Lokalisation |
Cytoplasm and Nucleus |
Factor XIIIa
|
Zeta Corporation |
ZM84 |
7 ml |
Ready-to-use |
CE/IVD |
Z2394MP |
-
|
Host |
Mouse |
Klon |
ZM84 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Capillary hemangioma, dermatofibroma, and placenta. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant fragment of human Factor XIIIa protein |
Lokalisation |
Cytoplasm and Nucleus |
Factor XIIIa
|
Zeta Corporation |
ZM84 |
0.5 ml |
Concentrate |
CE/IVD |
Z2394MS |
-
|
Host |
Mouse |
Klon |
ZM84 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Capillary hemangioma, dermatofibroma, and placenta. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Recombinant fragment of human Factor XIIIa protein |
Lokalisation |
Cytoplasm and Nucleus |
Factor XIIIa
|
Zeta Corporation |
ZM84 |
0.1 ml |
Concentrate |
CE/IVD |
Z2394MT |
-
|
Host |
Mouse |
Klon |
AC-1A1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Placenta |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
AC-1A1 |
1 ml |
Concentrate |
CE/IVD |
MOB321 |
-
|
Host |
Mouse |
Klon |
AC-1A1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Placenta |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
AC-1A1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB321-01 |
-
|
Host |
Mouse |
Klon |
AC-1A1 |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Placenta |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
AC-1A1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB321-05 |
-
|
Host |
Mouse |
Klon |
AC-1A1 |
Format |
Ready-to-use |
Methode |
F, P |
Positivkontrolle |
Placenta |
Verdünnung |
- |
Isotyp |
Mouse IgG1 |
Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
AC-1A1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM141 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
- |
Isotyp |
Rabbit IgG |
Verdünnung |
Recombinant protein corresponding to A-subunit of coagulation Factor XIIIa |
Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR054 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP103 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP103-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Placenta |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Rabbit IgG |
Lokalisation |
Cytoplasm, nucleus |
Factor XIIIa (Fibrinoligase, Plasma Transglutaminase)
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP103-05 |
-
|
Host |
Mouse |
Klon |
55K-2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin lymphoma, ovary |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
1 ml |
Concentrate |
CE/IVD |
MOB560 |
-
|
Host |
Mouse |
Klon |
55K-2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin lymphoma, ovary |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
0.1 ml |
Concentrate |
CE/IVD |
MOB560-01 |
-
|
Host |
Mouse |
Klon |
55K-2 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin lymphoma, ovary |
Verdünnung |
1:50 - 1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
0.5 ml |
Concentrate |
CE/IVD |
MOB560-05 |
-
|
Host |
Mouse |
Klon |
55K-2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin lymphoma, ovary |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
6 ml |
Ready-to-use |
CE/IVD |
PDM560 |
-
|
Host |
Mouse |
Klon |
55K-2 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Hodgkin lymphoma, ovary |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Cytoplasm |
Fascin
|
Diagnostic Biosystems |
55K-2 |
25 ml |
Ready-to-use |
CE/IVD |
PDM560-25 |
-
|
Host |
Mouse |
Klon |
ZM192 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin's lymphoma or spleen. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Full length recombinant human FSCN1 protein |
Lokalisation |
Cytoplasm |
Fascin
|
Zeta Corporation |
ZM192 |
1.0 ml |
Concentrate |
CE/IVD |
Z2446ML |
-
|
Host |
Mouse |
Klon |
ZM192 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin's lymphoma or spleen. |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Full length recombinant human FSCN1 protein |
Lokalisation |
Cytoplasm |
Fascin
|
Zeta Corporation |
ZM192 |
7 ml |
Ready-to-use |
CE/IVD |
Z2446MP |
-
|
Host |
Mouse |
Klon |
ZM192 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin's lymphoma or spleen. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Full length recombinant human FSCN1 protein |
Lokalisation |
Cytoplasm |
Fascin
|
Zeta Corporation |
ZM192 |
0.5 ml |
Concentrate |
CE/IVD |
Z2446MS |
-
|
Host |
Mouse |
Klon |
ZM192 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Hodgkin's lymphoma or spleen. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Full length recombinant human FSCN1 protein |
Lokalisation |
Cytoplasm |
Fascin
|
Zeta Corporation |
ZM192 |
0.1 ml |
Concentrate |
CE/IVD |
Z2446MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified by Protein A and peptide affinity chromatography |
Methode |
EL, WB, P |
Verdünnung |
5 - 20 µg/ml |
Isotyp |
Mouse IgG |
Verdünnung |
Recombinant protein corresponding Ser2-Ile127 from human FABP1, expressed in E. coli. |
Fatty Acid Binding Protein, Liver (FABP1, L-FABP)
|
Zytomed Systems GmbH |
polyclonal |
100 µl (0.2 mg/ml) |
Purified by Protein A and peptide affinity chromatography |
RUO |
206-0404 |
-
|
Host |
Rabbit |
Klon |
SP237 |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
P, FL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Endometrial Adenocarcinoma, Lung Squamous Cell Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human FBXW7 protein |
Lokalisation |
Cytoplasm, nucleus |
FBXW7
|
Zytomed Systems GmbH |
SP237 |
0.5 ml |
Concentrate |
RUO |
506-5372 |
-
|
Host |
Rabbit |
Klon |
SP237 |
Format |
Concentrate |
Reaktivität |
MS, RT |
Methode |
P, FL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Endometrial Adenocarcinoma, Lung Squamous Cell Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide derived from the internal region of human FBXW7 protein |
Lokalisation |
Cytoplasm, nucleus |
FBXW7
|
Zytomed Systems GmbH |
SP237 |
1 ml |
Concentrate |
RUO |
506-5374 |
-
|
Host |
Mouse |
Klon |
MC-GF1 |
Format |
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant |
Methode |
F, P, EL, WB |
Vorbehandlung |
- |
Verdünnung |
1:400 (P) |
Isotyp |
Mouse IgG2a |
Verdünnung |
Recombinant human bFGF |
FGFb (Fibroblast Growth Factor, Basic)
|
Zytomed Systems GmbH |
MC-GF1 |
500 µg |
Purified IgG prepared by affinity chromatography on Protein G from tissue culture supernatant |
RUO |
606-0075 |
-
|
Host |
Rabbit |
Klon |
SP273 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
stomach, adenocarcinoma |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
The exact immunogen sequence used to generate this antibody is proprietary information |
Lokalisation |
Cell membrane, cytoplasm |
FGFR2 (Fibroblast Growth Factor Receptor)
|
Zytomed Systems GmbH |
SP273 |
0.5 ml |
Concentrate |
RUO |
506-5732 |
-
|
Host |
Rabbit |
Klon |
SP273 |
Format |
Concentrate |
Methode |
P, FL |
Vorbehandlung |
Citrate |
Positivkontrolle |
stomach, adenocarcinoma |
Verdünnung |
1:100 |
Isotyp |
IgG |
Verdünnung |
The exact immunogen sequence used to generate this antibody is proprietary information |
Lokalisation |
Cell membrane, cytoplasm |
FGFR2 (Fibroblast Growth Factor Receptor)
|
Zytomed Systems GmbH |
SP273 |
1 ml |
Concentrate |
RUO |
506-5734 |
-
|
Host |
Sheep |
Klon |
polyclonal |
Format |
Purified |
Methode |
IF |
Verdünnung |
1:10 - 1:100 |
Isotyp |
Sheep IgG |
Verdünnung |
Native |
Fibrinogen (Coagulation Factor I) - FITC
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
606-0188 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Verdünnung |
1:20 - 1:40 |
Isotyp |
Rabbit Ig |
Fibrinogen-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F006 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Verdünnung |
1:20 - 1:40 |
Isotyp |
Rabbit Ig |
Fibrinogen-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F006-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
P |
Verdünnung |
10 µg/mL |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide: Extracellular domain of human FAP alpha conjugated to Keyhole Limpet Hemocyanin |
Fibroblast Activation Protein alpha (FAP alpha)
|
Zytomed Systems GmbH |
polyclonal |
50 µg |
Purified |
RUO |
606-0182 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Kidney |
Verdünnung |
1:50 - 1:250 |
Isotyp |
Rabbit IgG |
Lokalisation |
Basement Membrane, Connective Tissue |
Fibronectin
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP013 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Kidney |
Verdünnung |
1:50 - 1:250 |
Isotyp |
Rabbit IgG |
Lokalisation |
Basement Membrane, Connective Tissue |
Fibronectin
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP013-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
F, P |
Positivkontrolle |
Kidney |
Verdünnung |
1:50 - 1:250 |
Isotyp |
Rabbit IgG |
Lokalisation |
Basement Membrane, Connective Tissue |
Fibronectin
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP013-05 |
-
|
Host |
Rabbit |
Klon |
ZR217 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human FLI1 protein |
Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
1 ml |
Concentrate |
RUO |
Z2498RL-R |
-
|
Host |
Rabbit |
Klon |
ZR217 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Ewing's sarcoma/PNET, lymphoblastic lymphoma, lymphocytes, endothelial cells, angiosarcoma, Kaposi's sarcoma |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Recombinant full-length human FLI1 protein |
Lokalisation |
Nuclear |
FLI-1
|
Zeta Corporation |
ZR217 |
7 ml |
Ready-to-use |
RUO |
Z2498RP-R |
-
|